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Abstract:		High	blood	pressure,	screened	through	obtaining	a	patient’s	blood	pressure	(BP),	is	found	in	1	out	of	3	U.S.	adults	and	is	increasing	in	prevalence.6			A	cohort	of	39	subjects	had	their	BP	measured	following	American	Heart	Association	(AHA)	protocol,	utilizing	three	different	measurement	devices:	manual	sphygmomanometer	(MA),	automated	Midmark	IQvitals	(IQ),	and	an	automated	Omron	home	unit	(OM).		All	subjects	also	had	their	BP	measured	with	the	IQ	device	while	not	adhering	to	the	AHA	protocol.		The	two	protocol	conditions	were	denoted	PR	(protocol	following	AHA	guidelines)	or	TY	(typical	clinical	measurement	lacking	protocol).	The	results	demonstrated	a	mean	systolic	BP	with	IQ-TY	(123.7mmHg)	>	OM-PR	(118.3mmHg)	>	IQ-PR	(114.8mmHg)	>	MA-PR	(111.0mmHg),	all	statistically	significant	(p<0.01).	The	mean	diastolic	BP	for	IQ-TY	(79.6mmHg)	>	IQ-PR	(71.15mmHg),	OM-PR	(71.05mmHg),	and	MA-PR	(70.0mmHg),	with	IQ-TY	significantly	higher	than	the	other	3	(p<0.01).		When	comparing	the	number	of	participants	categorized	in	each	hypertension	stage,	IQ-TY	categorized	7participants	as	stage	1	hypertensive	while	OM-PR	categorized	3,	and	both	MA-PR	and	IQ-PR	only	categorized	1.		These	study	results	would	suggest	that	there	is	a	potential	for	possible	misclassification	of	patients	based	on	BP	protocol.			
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The	purpose	for	assessing	BP	is	to	determine	a	patient’s	risk	for	cardiovascular	disease.	An	elevated	BP	above	140	mmHg	is	referred	to	as	hypertension.			Hypertension	is	a	condition	that	exists	when	blood	is	being	pumped	through	the	vessels	at	a	very	high	rate	of	flow.		This	indirect	measure	of	the	perfusion	within	the	limbs	indicates	a	strain	on	the	heart,	blood	vessels,	kidneys,	and	other	vital	organs.		Physicians	in	the	20th	century	had	gained	the	ability	to	measure	BP	and	also	suspected	the	adverse	effects	of	hypertension,	with	few	treatment	options.1			Prior	to	the	implementation	of	certain	medications	diet	and	exercise	modification	were	the	only	treatments	to	manage	hypertension.	Untreated,	hypertension	can	damage	organs,	vessels,	and	can	increase	the	risk	for	a	heart	attack	or	stroke.2			If	left	untreated,	high	BP	can	stay	elevated	for	an	extended	length	of	time	and	cause	longitudinal	organ	and	vessel	damage.2	If	hypertension	is	caught	early,	the	detrimental	effects	can	be	limited	or	even	eliminated	through	change	of	diet	and	lifestyle	and/or	use	of	medication.		 Establishing	the	value	of	measuring	BP	as	a	screening	tool	for	hypertension	was	made	very	clear	by	the	American	Heart	Association	(AHA).		They	published	guidelines	that	categorize	BP	values	for	systolic	and	diastolic	readings.			The	primary	method	for	determining	the	stage	of	hypertension	is	measuring	a	patient’s	BP.		The	AHA’s	guidelines	indicate	that	a	normal	BP	measurement	should	be	less	than	120	mmHg	for	a	systolic	component	and	80	mmHg	for	the	diastolic	component	of	the	cardiac	cycle.3			The	different	blood	pressure	classifications	are	provided	in	Table	1,	based	on	AHA	guidelines	prior	to	Nov.	2017.	These	biometrics	allowed	a	clinician	to	use	this	indirect	measurement,	of	the	global	perfusion	in	the	upper	arm,	to	screen	patients	for	categories	of	hypertension	and	corresponding	cardiovascular	disease.		Ultimately	this	can	assist	in	developing	a	treatment	plan	for	the	hypertensive	patient.	Recently	BP	has	been	a	topic	of	discussion	in	the	medical	field	as	the	AHA	released	a	new	set	of	guidelines	in	Nov.	2017,	which	lowers	the	diagnostic	criteria.	The	new	classifications	are	provided	in	Table	2.4	Under	the	previous	categories	
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32%	of	the	US	population	was	considered	hypertensive.	Now	nearly	half	the	US	population,	46%,	would	be	considered	hypertensive.5	
	
Table	1:	The	American	Heart	Association’s	Diagnostic	Blood	Pressure	Categories	prior	to	Nov.	20173	
BP	Category	 Systolic	mm	Hg	 	 Diastolic	mm	Hg	
Normal	 Less	than	120	 And	 Less	than	80	
Prehypertension	 120-139	 Or	 80-89	
High	Blood	Pressure	
(Hypertension)	Stage	1	
140-159	 Or	 90-99	
High	Blood	Pressure	
(Hypertension)	Stage	2	
160	or	higher	 Or	 100	or	higher	
Hypertensive	Crisis	
(Emergency	care	
needed)	
Higher	than	180	 Or	 Higher	than	110	
	
	
Table	2:	The	American	Heart	Association’s	Diagnostic	Blood	Pressure	Categories	as	of	Nov.	20174	
Blood	Pressure	
Category	 Systolic	mm	Hg	 	 Diastolic	mm	Hg	
Normal	 Less	than	120	 And	 Less	than	80	
Elevated	 120-129	 And	 Less	than	80	
High	Blood	Pressure	
(Hypertension)	Stage	1	
130-139	 Or	 80-89	
High	Blood	Pressure	
(Hypertension)	Stage	2	
140	or	higher	 Or	 90	or	higher	
Hypertensive	Crisis	
(Emergency	care	
needed)	
Higher	than	180	 Or	 Higher	than	110	
		 Screening	patients	for	suspected	hypertension	and	corresponding	cardiovascular	disease	is	a	US	health	initiative.		The	Centers	for	Disease	Control	reported	that	approximately	1	in	3	U.S.	adults	(over	75	million	people)	have	high	BP	(Stage	1	or	2),	based	on	the	prior	AHA	guidelines.6	Of	those	US	adults,	about	half	(54%)	of	them	are	being	treated	and	have	their	BP	in	control.6	This	suggests	that	untreated/uncontrolled	high	blood	pressure	could	be	a	factor	contributing	to	the	cardiovascular	disease	that	exists	in	the	US.		It	also	underscores	the	importance	of	being	able	to	screen,	treat,	and	monitor	the	BPs	of	patients.		This	would	suggest	that	the	accuracy	of	recording	a	
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hypertensive	patient	is	paramount	to	properly	categorize	their	stage	of	disease	and	initiate	appropriate	treatment.		Recording	a	BP	is	an	indirect	screening	measurement	that	can	be	used	to	detect	hypertensive	patients	and	determine	whether	treatment	can	effectively	reducing	the	risk	of	heart	attack	and	stroke.		
Literature	review		Blood	Pressure	measurement	devices	are	classified	as	Class	II	medical	devices	and	therefore	fall	under	the	section	510(k)	clearance	from	the	FDA.	510(k)	was	first	introduced	in	1976	and	has	had	several	minor	changes	throughout	the	years.	In	order	to	receive	clearance,	the	manufacturer	must	notify	the	FDA	of	their	intent	to	sell	and	must	provide	evidence	of	the	device’s	safety	and	efficacy.7	The	evidence	provided	from	the	manufacturer	can	come	from	within	the	organization,	from	a	3rd	party,	or	a	combination	of	both.	Therefore	it	is	important	to	further	investigate	the	validity	of	equipment	for	at	least	two	reasons.	First,	manufacturers	are	invested	in	their	product	and	may	inadvertently	influence	the	research	conducted.	Second,	tests	are	done	in	a	controlled	research	setting,	which	may	not	be	applicable	to	clinical	practice.			 Over	the	past	couple	of	decades,	the	method	of	measurement	for	BP	has	seen	major	changes.	Mercury	manometers	were	considered	the	“gold	standard,”	but	due	to	mercury’s	toxicity	the	U.S.	Environmental	Protection	Agency	(EPA)	mandated	that	all	mercury	products	be	removed	from	hospitals	by	2005.8	Therefore,	to	be	compliant,	other	methods	of	BP	assessment,	such	as	automated	devices,	were	adopted	in	order	to	accurately	assess	hypertension	and	also	to	comply	with	the	EPA	mandate.		Naturally,	this	shift	has	created	concerns	about	the	validity	of	automated	techniques	to	accurately	measure	BP	among	providers	who	have	been	using	manual	techniques	in	their	practice	for	years.8	As	the	EPA	mandate	was	taking	effect,	the	AHA	was	revisiting	their	guidelines	since	it	had	been	over	10	years	since	they	had	last	posted	recommendations,	over	which	time	new	information,	technology,	and	techniques	had	surfaced.	
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	 Along	with	the	EPA	mandate,	there	was	a	major	change	in	recording	BP,	which	meant	moving	from	fully	auscultatory	techniques	with	a	mercury	device,	to	electronic	transducers,	and	then	finally	adopting	fully	automated	devices.	In	order	to	standardize	across	the	various	equipment,	Pickering	et	al.	developed	a	standard	protocol	by	determining	how	different	positions	affected	BP	readings,	such	that	an	accurate	diagnostic	measurement	could	be	determined.	Their	findings	determined	the	best	position	is	for	the	patient	to	be	seated	with	the	feet	and	back	supported,	feet	uncrossed,	arm	supported	at	heart	level,	cuff	on	bare	skin,	no	talking	or	active	listening,	resting	quietly	and	comfortably	in	a	seated	position	for	3-5	minutes	prior	to	measurement,	with	a	proper	deflation	rate	of	2-3	mm	Hg	per	sec.9	Failure	to	follow	this	protocol	can	significantly	affect	BP	values.		No	back	support	has	been	shown	to	increase	BP	by	approximately	6	mm	Hg.9	Crossed	legs	increases	BP	by	approximately	2-8	mm	Hg.9	The	arm	not	at	heart	level	can	change	BP	by	10	mm	Hg	or	more	(arm	above	the	heart	decreases	BP,	while	arm	below	the	heart	increases	BP).9		The	study	also	found	inaccuracies	in	BP	due	to	improper	cuff	size	and	fear	of	the	physician	(also	referred	to	as	“white	coat	syndrome”),	which	is	the	elevation	of	a	patient’s	BP	when	a	provider	is	in	the	room	taking	the	measurement.		This	same	protocol	has	been	adopted	and	promoted	by	Johns	Hopkins	University,	and	is	the	preferred	protocol	for	this	study.		Pickering	et	al.	also	discussed	taking	multiple	measurements,	stating	the	first	reading	is	always	the	highest	and	there	should	be	at	least	1	minute	between	readings.9			 Accurate	and	reliable	BP	measurement	protocols	are	important	because	it	is	a	crucial	measure	of	a	person’s	health.	Improper	BP	measurements	can	have	detrimental	effects.	In	a	case	study	published	by	Handler,	a	72	year	old	female	patient	had	a	recorded	BP	of	150/70	in	the	office	but	reported	readings	of	128/64	at	home.10	The	following	questions	were	posed	as	explanations	for	this	disparity:	whether	or	not	the	patient	had	“white	coat	syndrome,”	the	measurement	in	office	was	incorrect,	or	the	measurement	at	home	was	falsely	reported.		The	difference	in	home	and	office	measurements	for	this	patient	corresponded	to	a	diagnosis	decision	between	pre-hypertensive	and	
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stage	1	hypertension,	which	could	have	led	to	prescribing	BP	medication.	An	investigation	determined	that	improper	protocol	was	the	cause	of	the	elevated	BP	office	reading	due	to	talking	and	active	listening	during	the	measurement.10		 As	the	popularity	of	automated	blood	pressure	measurements	rises,	they	are	beginning	to	replace	manual	sphygmomanometers	(devices	used	to	measure	BP)	in	clinical	practice.	Myers	et	al.	investigated	this	trend	through	analysis	of	previous	comparison	studies.	When	manual	BP	readings	done	in	a	controlled	research	environment	were	compared	to	manual	BP	readings	done	in	a	typical	provider	office	visit,	the	clinical	office	readings	were	on	average	10	to	5	mmHg	higher	for	systolic	and	diastolic	readings,	respectively.11	Was	the	change	due	to	lack	of	protocol,	varied	skill	of	the	professional	taking	the	measurement,	or	other	variables?	Myers	et	al.	examined	studies	comparing	automated	and	manual	office	BP	to	measures	indicating	possible	target	organ	damaged.	A	significant	correlation	was	found	between	the	automated	BP	unit	and	target	organ	damage,	but	not	with	the	manual	unit.11	In	order	for	the	difference	in	association	between	the	equipment,	the	BP	readings	had	to	be	varied.		An	investigation	by	Myers	et	al.	conclude	there	is	little	reason	to	continue	use	of	manual	BP	readings	in	clinical	practice.	They	believe	automated	units	and	home	BP	units	produce	better	results	than	the	manual	readings	done	in	clinical	practice.11	Overall	the	literature	has	little	evidence	directly	comparing	an	automated	unit,	manual	unit,	and	home	BP	unit	together	in	a	controlled	manner.	Further,	a	comparison	of	BP	measured	with	an	automated	BP	device	strictly	following	the	AHA	protocol	compared	to	BP	measured	with	an	automated	BP	using	more	common	clinical	practice	has	yet	to	be	done.	The	current	study	was	devised	to	investigate	the	relationship	between	manual,	automated	clinical,	and	automated	home	BP	measurement	devices,	as	well	as	the	effect	of	protocol	divergence	on	BP	measurements,	and	the	effect	of	resting	time	prior	to	measurement.			The	following	hypotheses	were	proposed:		1. There	is	no	difference	in	BP	measurements	taken	using	a	manual	sphygmomanometer,	a	clinical	vitals	automated	unit,	or	an	automated	home	unit.		
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2. There	is	a	difference	in	BP	measured	following	the	AHA	protocol	and	traditional	protocol	that	lacks	AHA	protocol	rigor.	2.1:	There	is	a	difference	in	BP	measured	at	time	0	(Trial	1)	and	BP	measured	at	time	8	(Trial	5),	during	traditional	clinical	BP	measurement,	specifically	testing	the	effect	of	3-5	min.	of	rest	on	measured	BP.	
Materials	and	Methods		The	study	employed	a	repeated	measures	design	to	examine	the	effects	of	three	independent	variables:		measurement	device	(3	levels:		manual	sphygmomanometer,	clinical	vitals	automated	unit,	and	automated	home	unit),	protocol	(2	levels:		AHA	protocol	and	typical	clinical),	and	resting	time.		The	variables	were	not	fully	crossed;	see	Table	3.		This	pilot	study	adopted	the	AHA/Johns	Hopkins	University	protocol	for	recording	BP	in	order	to	compare	measurement	devices.		Protocol	effect	was	assessed	by	comparing	AHA	protocol	BP	to	BP	measured	while	not	adhering	to	the	AHA	protocol;	this	effect	was	only	examined	using	the	clinical	automated	device.			Thirty-nine	individuals	participated	in	the	study,	which	was	approved	by	The	Ohio	State	University’s	Institutional	Review	Board.		 The	devices	used	in	the	study	were	a	Tycos	Jewel	Movement	manual	sphygmomanometer,	a	Midmark	IQVitals	automated	clinic	vitals	measuring	device,	and	an	Omron	(model:	BP742)	automated	home	BP	measurement	device.		The	study	consisted	of	three	different	parts:	consent	process,	common	clinical	measurement,	and	baseline	data	measurement.	The	data	were	collected	on	data	sheets	and	transferred	to	an	ExcelTM	spreadsheet.	The	records	were	kept	in	a	secure	file	in	the	PI’s	office	along	with	the	ExcelTM	spreadsheets	on	a	password-encrypted	university	server.	All	of	the	BP	measurements	were	shared	with	the	participant	for	their	benefit.	The	participants	were	directed	to	ask	their	physician	if	they	had	any	questions	about	their	measurements.		
	 The	consent	process	involved	explanation	of	the	experiment,	protocol,	and	consent	form.	The	same	scripted	explanation	was	given	to	all	participants	before	the	researchers	left	the	room	to	
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allow	the	participant	time	to	look	over	the	material.	The	researcher	returned	in	three	minutes	and	answered	any	questions	the	participant	had.		If	the	participant	provided	consent,	the	participant	was	reminded	that	his/her	participation	was	voluntary,	so	he	or	she	can	decline	and	leave	at	any	point;	the	researcher	then	collected	the	consent	form	and	began	the	common	clinical	measurement.		If	the	participant	did	not	consent	to	the	study,	he	or	she	was	thanked	for	their	time	and	was	led	to	the	exit.		
	 The	typical	clinical	measurement	was	taken	using	Midmark’s	IQvitals.	The	participant’s	position	for	these	measurements	was	based	on	observations	of	the	vitals’	acquisition	process	at	multiple	outpatient	primary	care	facilities.	The	set-up	of	the	room	was	similar	to	those	observed	at	several	local	doctors’	offices.	There	was	an	exam	table	that	does	not	support	the	back	or	feet	of	the	participant.	The	participant	never	had	their	arm,	feet,	or	back	supported.	Since	there	was	no	overt	instruction,	the	participant	may	have	had	their	legs	crossed	and/or	been	talking.	The	process	began	by	obtaining	the	participant’s	demographics,	which	included	mass	(kg),	height	(cm),	age	(years),	and	sex	(M	or	F).	Then	the	participant	was	walked	to	the	elevator	on	the	second	floor	of	the	research	facility	and	was	guided	by	the	researcher	back	into	the	room	where	the	other	measurements	were	taken.	The	participant	was	seated	up	on	the	exam	table.	The	researcher	then	put	the	cuff	on	the	participant	and	immediately	measured	their	BP.	Time	zero	was	when	the	participant	sat	down.	The	time	the	first	measurement	(trial	1)	was	taken	was	recorded.	The	participant	remained	in	the	same	position	and	4	more	measurements	were	taken	with	a	minute	in-between	each	measurement.	The	time	was	recorded	as	seconds	elapsed	since	time	0.	At	the	time	of	each	measurement	it	was	recorded	whether	the	participant	was	talking	or	not.		
	 Baseline	data	was	measured	using	the	three	different	devices:	a	traditional	manual	sphygmomanometer,	Midmark’s	IQvitals,	and	an	Omron	(model:	BP742)	portable	home	BP	device.	The	order	in	which	the	devices	were	used	was	randomized	for	each	participant.	With	each	device,	the	researcher	followed	the	AHA/Johns	Hopkins	University	BP	measurement	protocol:	feet	and	
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back	supported,	feet	uncrossed,	arm	supported	at	heart	level,	cuff	on	bare	skin,	resting	for	3-5	minutes,	with	no	talking	or	active	listening	during	measurement.	Three	measurements	were	taken	with	each	device.	There	was	a	3-minute	rest	period	prior	to	the	first	measurement	with	each	device	and	a	1	minute	pause	in	between	each	measurement.			 The	independent	variables	were	the	types	of	equipment	used	to	record	the	BP,	as	well	as	following	the	protocol	vs.	non-protocol.		The	types	of	equipment	were	coded	as	MA	(manual	sphygmomanometer),	IQ	(Midmark’s	IQvitals	automated),	and	OM	(Omron	home	automated	unit).		The	conditions	were	coded	as	PR	(adherence	to	protocol,	the	‘baseline’	data)	and	TY	(typically	observed	in	the	clinical	setting,	the	‘typical	clinical	measurement’).	Due	to	participant	consented	time	restraints,	IQ	was	the	only	equipment	used	to	test	the	TY	condition.	All	the	equipment	was	tested	in	the	PR	condition.	The	type	of	equipment	was	coded	as	a	categorical	variable.	The	dependent	variable	was	the	recorded	BP	measurement,	therefore	this	is	ratio	data.	
Table	3.		Trial	labeling	for	each	of	the	14	measurements	based	on	condition	and	equipment.	
Condition:	 Typical	Clinical	Measurement	 AHA/Johns	Hopkins	Protocol	
Repetition:	 1	 2	 3	 4	 5	 1	 2	 3	
Equipment:	
IQ	 IQ-TY	 IQ-TY	 IQ-TY	 IQ-TY	 IQ-TY	 IQ-PR	 IQ-PR	 IQ-PR	
OM	 	 	 	 	 	 OM-PR	 OM-PR	 OM-PR	
MA	 	 	 	 	 	 MA-PR	 MA-PR	 MA-PR		 Effects	of	protocol	conditions	and	equipment	were	examined	in	this	study	by	collected	data	in	the	marked	cells	of	Table	3.		Typical	clinical	measurements	(TY)	were	compared	to	protocol	(PR)	measurements	using	only	the	Midmark	IQVitals	(IQ)	automated	measurement	device;	this	allowed	assessment	of	effects	of	protocol	method.		Equipment	effect	was	assessed	by	comparing	measurements	made	using	the	Midmark	IQVitals	(IQ)	automated	device,	Omron	(OM)	automated	device,	and	a	manual	sphygmomanometer	(MA),	using	the	AHA/Johns	Hopkins	protocol	(PR).	
	
Statistical	analysis		
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Descriptive	statistics	were	planned	to	be	calculated	and	reported.		The	data	was	then	analyzed	to	check	for	normality.		Given	the	data	were	normally	distributed,	descriptive	statistics	were	reported	using	means,	medians,	and	standard	deviations.			A	priori,	the	statistical	significance	was	set	at	p	<	0.05.				
• Hypothesis	1	(the	effect	of	equipment):	an	analysis	of	variance	(ANOVA)	was	performed	to	compared	the	differences	in	the	measurements	of	BP	using	a	manual	sphygmomanometer,	the	IQvitals,	and	the	Omron	home	unit.	 
• Hypothesis	2	(the	effect	of	condition):	a	paired	t-test	was	performed	to	compare	differences	in	the	measurement	of	BP	following	AHA	protocol	with	the	IQvitals	and	lack	of	protocol	(traditional)	with	the	IQ	vitals.	 
o Hypothesis	2.1	(effect	of	rest	time):	a	paired	t-test	was	anticipated	to	compare	differences	in	measured	BP	in	trial	1,	immediately	after	sitting	down,	and	in	trial	5,	after	8	minutes	of	rest;	this	was	only	tested	for	the	traditional	protocol.		
Results	Demographic	data	from	the	sample	of	39	participants	is	displayed	in	Tables	4	and	5.		The	majority	of	the	participants	were	young	adults	with	a	median	age	of	23	years	with	an	even	distribution	of	males	(46%)	and	females	(54%).		Despite	the	majority	of	participants	being	in	their	20’s,	there	was	a	wide	range	of	ages,	18	-	59	years.	Over	half	of	the	participants	were	at	a	healthy	weight	(59%	<25	BMI)	and	only	8%	of	the	participants	took	BP	medication.		
Table	4:	The	sample	cohort’s	descriptive	statistics	for	age	and	BMI.	
Variable	 N	 Mean	 SE	
Mean	
SD	 Minimum	 Q1	 Median	 Q3	 Maximum	
Age	
(years)	
39	 27.5	 1.7	 10.4	 18.0	 21.0	 32.0	 33.0	 59.0	
BMI	 39	 24.6	 0.5	 3.0	 19.4	 22.8	 23.9	 26.6	 31.9	
 
 
Table	5:	The	sample	cohort’s	descriptive	statistics:	categorical	descriptions	of	gender	and	BMI.	
Sex	 Count	 Percent	 BP	Meds	 Count	 Percent	 BMI	 Count	 Percent	
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(1	or	0,	
1=yes)	
F	 21	 53.8	 0	 36	 92.3	 <25	 23	 59.0	
M	 18	 46.2	 1	 3	 7.7	 25-30	 13	 33.3	
Total	 39	 	 Total	 39	 	 Total	 39	 		The	descriptive	statistics	for	the	systolic	(SYS)	and	diastolic	(DIA)	BP	measurement	for	each	type	of	equipment	is	displayed	in	Tables	6	and	7.		The	systolic	BP	endpoint	had	a	highest	to	lowest	value	recorded,	based	on	equipment	type.		Looking	at	equipment	only,	the	ranking	of	the	systolic	BP	endpoint	had	the	highest	value	with	OM-PR,	followed	by	IQ-PR.		The	lowest	value	was	MA-PR.		The	comparison	of	all	the	systolic	endpoint	data,	based	on	equipment	type	were	all	statistically	significant	(P<0.001).	MA-PR	has	38	instead	of	39	data	points	because	there	was	an	outlier	at	82.7	mmHg.	The	diastolic	BP	endpoint,	had	a	similar	highest	to	lowest	value	range	recorded,	based	on	equipment	type.		The	ranking	of	the	diastolic	BP	endpoint	had	the	highest	value	recorded	with	IQ-PR	followed	by	OM-PR.		The	lowest	value	was	MA-PR.	The	comparison	of	all	the	diastolic	BP	endpoint	data,	based	on	equipment	type,	produced	no	statistical	difference	between	diastolic	BP.		
Table	6:	Descriptive	Statistics	for	Systolic	BP	measurement	of	IQ-TY,	IQ-PR,	OM-PR,	and	MA-PR	
Variable	 N	 Mean	 SE	
Mean	
SD	 Minimum	 Q1	 Median	 Q3	 Maximum	
IQ-TY	
Systolic	
39	 123.7	 1.8	 11.5	 106.2	 116.2	 120.8	 131.6	 153.8	
IQ-PR	
Systolic	
39	 114.8	 1.6	 9.9	 95.3	 108.7	 111.7	 12.0	 143.7	
OM-PR	
Systolic	
39	 118.3	 2.0	 12.6	 97.3	 108.7	 116.7	 125.3	 150.0	
MA-PR	
Systolic	
38	 111.8	 1.7	 10.2	 93.3	 105.3	 110.5	 116.2	 140.7	
 
 
 
 
Table	7:	Descriptive	Statistics	for	Diastolic	BP	measurement	of	IQ-TY,	IQ-PR,	OM-PR,	and	MA-PR	
Variable	 N	 Mean	 SE	
Mean	
SD	 Minimum	 Q1	 Median	 Q3	 Maximum	
IQ-TY	
Diastolic	
39	 79.6	 1.6	 9.8	 57.8	 73.2	 76.4	 86.8	 101.8	
IQ-PR	
Diastolic	
39	 71.2	 1.3	 8.1	 55.0	 65.0	 72.0	 77.0	 87.0	
OM-PR	
Diastolic	
39	 71.1	 1.3	 8.1	 58.3	 65.3	 70.7	 77.3	 88.7	
MA-PR	 39	 70.0	 1.2	 7.2	 58.0	 64.5	 70.0	 74.0	 85.3	
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Diastoic		The	descriptive	statistics	for	comparison	of	condition	can	also	be	found	in	Tables	6	and	7.		IQ-TY	was	found	to	be	significantly	higher	than	IQ-PR	for	both	systolic	and	diastolic	BP.		 Reviewing	Figure	1	demonstrates	a	comparison	of	rest	time	when	reviewing	IQ-TY’s	first	systolic	BP	endpoint,	at	time	0	(measurement	1),	compared	to	the	last	systolic	BP	endpoint,	at	time	8	minutes	(measurement	5),	as	well	as	the	first	diastolic	BP	endpoint,	at	time	0	(measurement	1),	compared	to	the	last	diastolic	BP	endpoint,	at	time	8	minutes	(measurement	5).		The	decrease	from	the	first	to	last	measurement	was	found	to	be	statistically	significant	for	both	systolic	(-7.33,	P<0.0001)	and	diastolic	(-2.87,	P=0.005).			
Figure	1:	IQ-TY	BP	Collected	from	Trial	1	vs	Trial	5	
 		 Additional	statistical	analysis	was	done	to	further	evaluate	the	data	and	associated	findings.		The	matrix	plots	in	Figures	2	and	3	visually	compare	the	systolic	and	diastolic	BP	measurements,	respectively,	across	each	type	of	equipment.	The	line	on	each	graph	represents	where	the	data	point	would	be	if	the	same	BP	measurement	value	was	recorded	for	the	conditions	compared.	MA-
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PR	produced	systolic	BP	measurements	that	were	lower	than	all	of	the	other	methods,	for	nearly	all	the	participants	(See	Figure	1,	bottom	row).	OM-PR	recorded	higher	systolic	BP	measurements	than	IQ-PR	(See	Figure	1,	row	2	column	3).	A	similar	ranking	of	data	was	noted	when	reviewing	the	diastolic	BP	measurements,	though	the	diastolic	endpoints	taken	with	IQ-PR,	OM-PR,	MA-PR	all	appear	to	be	much	closer	in	value	than	the	systolic	endpoints.			
Figure	2:	Systolic	Comparison	between	equipment	and	conditions,	separated	by	gender. 
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Figure	3:	Diastolic	BP	measurement	comparison	between	equipment	and	conditions,	separated	by	gender.
		It	was	decided	to	add	strength	of	association	between	each	equipment	type	used	to	measure	systolic	and	diastolic	endpoints.		Tables	8	and	9	provide	the	correlation	coefficient	and	statistical	significance	when	comparing	the	equipment	type	for	recording	systolic	and	diastolic	BP	measurements.		Measurements	made	with	the	different	devices	were	highly	correlated,	with	most	having	a	strength	of	association	around	0.9.	The	only	comparison	that	was	noticeably	different	was	the	correlation	between	the	OM-PR	and	IQ-TY,	which	was	still	strong	at	0.78.	Similarly,	the	diastolic	BP	endpoint	taken	with	the	different	devices	demonstrated	a	similar	strength	of	association	with	coefficients	between	0.8	and	0.9.		All	the	correlations	were	statistically	significant	(p<	0.05).				
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Table	8:	Systolic	Endpoints	Correlated	between	equipment	and	condition.	
Systolic	endpoints	 Mean	IQ-TY	 Mean	IQ-PR	 Mean	OM-PR	
Mean	IQ-PR	 R=0.90;	p<	0.05	 	 	
Mean	OM-PR	 R=	0.78;p<	0.05	 R=	0.9;	p<	0.05	 	
Mean	MA-PR	 R=	0.91;	p<0.05	 R=	0.93;	p<	0.05	 R=0.9;	p<	0.05	
 
 
Table	9:	Diastolic	Endpoints	Correlated	between	equipment	and	condition.	
Diastolic	endpoints	 Mean	IQ-TY	 Mean	IQ-PR	 Mean	OM-PR	
Mean	IQ-PR	 R=0.81;	p<	0.05	 	 	
Mean	OM-PR	 R=	0.86;p<	0.05	 R=	0.84;	p<	0.05	 	
Mean	MA-PR	 R=	0.79;	p<0.05	 R=	0.75;	p<	0.05	 R=0.90;	p<	0.05			 The	pooled	standard	deviations	for	systolic	and	diastolic	blood	pressure	across	all	three	types	of	equipment	are	displayed	in	Figure	4.	Based	on	observation,	each	subject	appeared	to	have	a	wide	range	of	readings.	Comparing	the	measurement	variance	from	repeated	measures,	as	displayed	in	Table	10,	the	IQ	vitals	unit	had	the	most	measurement	variance.	The	measurements	taken	with	IQ-PR	had	the	most	systolic	measurement	variance	of	4.1	mm	Hg.		The	measurements	taken	with	IQ-PR	had	the	most	diastolic	measurement	variance	of	6.3	mm	Hg.	The	MA-PR	use	had	the	least	systolic	measurement	variance	while	OM-PR	had	the	least	diastolic	measurement	variance.		
Figure	4:	Pooled	Standard	Deviations	for	Systolic	and	Diastolic	Pressure	
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Table	10:	Equipment	and	Protocol	BP	Measurement	Error	
		 SYS	 DIA	
IQ-TY	 6.58	 4.59	
IQ-PR	 4.12	 6.26	
OM-PR	 3.77	 2.42	
MA-PR	 3.42	 2.82		Figure	5	demonstrates	how	each	participant	would	be	classified	using	the	current	AHA	hypertension	guidelines.	The	MA-PR	equipment	measurements	classified	most	of	the	participants	as	having	a	normal	BP	(N=31),	while	the	IQ-PR	data	classified	fewer	participants	as	normal	(N=28).	The	use	of	OM-PR	for	generating	BP	data	classified	participants	differently	with	the	cohort	as	normal	(N=24),	elevated	(N=12)	and	stage	1	hypertension	(N=3).	Based	on	equipment,	OM-PR	classified	more	participants	as	both	prehypertension	and	stage	1	hypertension	compared	to	IQ-PR	and	MA-PR.	
Figure	5:	The	cohort’s	classification	using	the	current	American	Heart	Association’s	Hypertension	Categories.	
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The	same	additional	measures	used	to	compare	the	equipment	were	also	useful	to	compare	the	different	conditions.	Referring	to	the	top	row	in	Figure	2,	IQ-TY	produced	systolic	BP	measurements	that	were	higher	than	the	other	methods	for	nearly	all	the	participants.	In	Tables	8	and	9	it	can	be	noted	that	IQ-TY	had	a	high	significant	correlation	between	all	the	equipment	for	both	systolic	and	diastolic	BP	measurements.	The	lowest	correlation	was	0.8.	In	table	9	the	measurement	variance	for	IQ-TY	can	be	seen	as	6.58	mmHg	for	systolic	and	4.59	mmHg	for	diastolic.	The	systolic	was	higher	while	the	diastolic	had	a	lower	measurement	variance	compared	to	IQ-PR.	When	using	IQ-TY	to	classify	participants	in	hypertension	stage,	the	data	generated	classified	participants	as	either	normal	(N=15),	elevated	(N=16),	stage	1	hypertension	(N=7),	or	stage	2	hypertension	(N=1)	as	seen	in	Figure	5.	IQ-TY	classified	the	most	people	as	pre-hypertensive,	stage	1	hypertension,	and	was	the	only	method	to	have	an	individual	as	stage	2	hypertension	compared	to	all	the	other	equipment.			 Additional	data	analyses	were	completed	to	determine	the	strength	of	relationship	between	the	difference	of	IQ-PR	and	IQ-TY	based	on	gender,	BMI,	BP	medication,	or	age.		None	of	these	additional	comparisons	proved	to	be	statistically	significant.	When	considering	that	participants	were	allowed	to	talk	during	the	BP	data	collection,	this	condition	did	not	prove	to	significantly	increase	systolic	BP.		The	average	increase	in	the	systolic	BP	endpoint,	due	to	talking,	was	only	0.83	mm	Hg	with	a	standard	error	of	1.11	(p=0.46).	However	allowing	participants	to	talk	during	the	BP	data	collection	did	prove	to	significantly	increase	the	diastolic	BP	endpoint	by	an	average	increase	of	1.88	mm	Hg	with	a	standard	error	of	0.7	(p=0.01).			 An	intraclass	correlation	coefficient	(ICC)	was	used	to	determine	the	reproducibility	of	the	data	obtained;	for	systolic	it	was	0.87	and	for	diastolic	it	was	0.81.						
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Discussion		This	cohort	was	recruited	from	a	medical	campus	of	college-aged	students	and	employees	of	various	ages	and	backgrounds.	With	54%	of	the	participants	being	female,	mean	age	of	27.5	yrs,	and	average	BMI	of	24.6	this	cohort	of	participants	appears	to	have	a	lower	BMI	in	comparison	to	the	US	population	average	BMI,	which	is	26.5.12	Along	with	a	healthier	body	composition,	this	cohort	of	participants	also	had	lower	hypertension	trends	than	the	US	population.	The	US	trend,	under	the	old	guidelines	(BP	140/90	or	above)	for	hypertension	among	those	20	years	and	older	was	30%,	however	in	the	survey,	most	in	the	cohort	were	older.13			In	that	same	survey	group,	those	20-44	years	of	age,	which	is	more	comparable	to	the	current	pilot	sample	of	participants	since	the	mean	age	was	27.5,	had	a	rate	of	hypertension	of	12%.13	This	was	based	on	the	old	guidelines,	so	this	number	would	be	even	higher	if	the	new	guidelines	were	used.	Basing	hypertension	purely	on	a	BP	measurement	of	140/90	or	higher	(the	old	guidelines	so	an	even	comparison	can	be	made),	no	participant	was	hypertensive	when	following	protocol	on	any	equipment.	The	US	trend	for	hypertension	also	indicates	33%	of	those	20	years	and	older	are	at	risk	for	hypertension.13	This	risk	for	younger	people	is	alarming	and	careful	detection	of	an	elevated	BP	is	a	means	towards	addressing	the	tendency	for	developing	cardiovascular	disease.		 Blood	pressure	is	a	vital	sign	taken	by	providers	in	outpatient	and	inpatient	facilities,	serving	as	an	indicator	for	numerous	diseases	from	the	common	cold	to	serious	cardiovascular	disease.	Elevated	blood	pressure	itself	has	the	potential	to	lead	to	dangerous	conditions	such	as	stroke	or	heart	attack.	The	significant	discrepancy	between	equipment	and	protocol	should	underscore	the	need	for	consistency	and	accuracy	when	this	critical	vital	sign	is	being	measured.			 First,	taking	the	equipment	into	consideration,	in	the	past	several	decades	there	has	been	a	trend	away	from	manual	and	towards	automated	BP	measurement.	With	this	transition	came	resistance	due	to	not	knowing	how	to	handle	potential	discrepancies	in	the	biometric	data.	Was	the	machine	or	the	provider	the	source	of	inaccuracy?	Based	on	the	results	of	the	current	study,	there	
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was	a	significant	difference	between	devices	for	the	systolic	BP,	but	not	for	the	diastolic	BP.	The	home	unit	had	the	highest	BP	measurements,	while	manual	had	the	lowest.	Due	to	the	ordered	(OM-PR>IQ-PR>MA-PR)	significant	difference	for	systolic	BP,	hypothesis	1	has	to	be	rejected.	Literature	produced	from	the	clinical	setting	found	slightly	different	results.		Myers	and	colleagues	found	automated	units	to	produce	significantly	lower	measurements	than	manual	methods	and	concluded	that	automated	units	have	higher	quality	and	accuracy	due	to	the	ability	to	reduce	digit	preference	and	white	coat	response,	both	of	which	were	not	studied	in	the	current	study.14	Digit	preference	is	the	tendency	to	round	a	number	so	the	one’s	digit	is	a	0	or	a	5	when	recording	manual	BP.	White	coat	response	is	the	tendency	for	an	individual’s	BP	to	raise	when	it	is	measured	in	a	clinical	setting.	Mirdamadi,	et	al.,	as	well	as	Eteban	et	al.	also	found	manual	BP	measurement	to	be	significantly	higher	than	automated	measurement.15	A	separate	study	by	executed	by	Mansoor	and	colleagues,	within	the	emergency	department,	concluded	that	automated	units	produce	readings	that	are	too	varied	to	be	considered	reliable	for	use	in	the	ED.16	The	spectrum	of	information	found	in	the	present	study	as	well	as	the	literature	makes	it	apparent	that	further	investigation	of	the	differences	between	manual	and	automated	units	is	needed.	It	is	important	to	keep	in	mind	that	this	study	did	not	account	for	white	coat	effect,	which	can	be	a	major	benefit	of	automated	units.		All	the	variation	raises	the	important	question	of	what	is	the	most	accurate	means	to	measure	the	patient’s	blood	pressure.		 Next,	based	on	comparing	the	two	measurement	protocols,	condition	(protocol)	appeared	to	be	a	more	influential	factor	than	equipment,	though	this	was	only	tested	with	one	of	the	devices.	The	lack	of	protocol	produced	significantly	higher	systolic	and	diastolic	BP	measurements	than	the	protocol	measurements.	This	is	evident	in	the	higher	systolic	end	point	for	IQ-TY	(123.7	mmHg)	compared	to	IQ-PR	(114.8	mmHg),	as	well	as	the	higher	diastolic	end	point	of	IQ-TY,	79.6	mmHg,	compared	to	IQ-PR,	71.15	mmHg.	The	effect	of	a	lax	protocol	can	also	be	easily	visualized	in	figures	2	and	3,	which	show	nearly	all	the	data	points	clustered	above	the	regression	line	for	the	graphs	
20 
 
involving	IQ-TY’s.	The	dramatic	increase	in	BP	for	IQ-TY	allows	hypothesis	2	to	be	confirmed.		By	examining	the	ranges	of	the	axes	in	Figures	2	and	3	it	is	obvious	that	lack	of	protocol	is	much	more	influential	than	equipment	(though	this	statement	is	limited	by	the	fact	that	the	effect	of	protocol	was	only	tested	using	the	IQvitals	device.	In	order	to	obtain	the	best	BP	measurement	to	create	a	patient	trend,	it	is	imperative	that	protocol	is	consistently	followed.	That	way	when	there	is	an	increase	or	decrease	in	BP,	the	provider	can	assume	it	is	due	to	a	physiological	change.	There	is	already	conflict	over	natural	variation	in	BP	and	whether	episodic	or	maximum	BP	is	meaningful.	The	natural	variation	in	BP	is	used	to	assess	cardiovascular	risk.	Dr.	Rothwell	discusses	this	variation	in	BP	and	how	it	is	used	in	the	clinical	setting	to	diagnosis	diseases.	Rothwell	also	warns	against	relying	too	much	on	a	single	measurement	as	there	are	natural	fluctuations	depending	on	surrounding	environment,	but	variation	in	BP,	especially	increases,	can	be	signs	of	atrial	disease	and/or	organ	damage.17	If	this	perceived	“natural”	is	merely	just	an	inconsistency	in	protocol	used,	then	the	diagnosis	and	treatment	could	be	wrong	and	detrimental	to	the	patient.		 An	interesting	discovery	when	comparing	IQ-TY	and	IQ-PR	is	that	the	mean	increase	for	the	systolic	BP	is	only	9	mmHg	and	increase	in	diastolic	BP	is	only	8	mmHg.	The	difference	between	the	two	measurements	is	the	participant	had	their	feet	elevated	from	the	ground	(+5-10	mmHg),	back	unsupported	(+5-10	mmHg),	arm	unsupported	(+10	mmHg),	non-resting	for	3-5	minutes	(+10-20	mmHg),	and	potentially	talking	(+10-15mmHg)	in	IQ-TY.9	If	the	different	variables	were	cumulative,	then	they	would	add	up	to	an	increase	of	at	least	30	mmHg.	The	increase	seen	in	this	pilot	study	with	condition	TY	was	less	than	10	mmHg.	This	confirms	that	the	variables	necessary	to	follow	protocol	and	obtain	a	proper	BP	are	not	additive,	consistent	with	the	literature.9	Therefore	the	patient	could	have	the	same	elevated	BP	if	1	or	5	variables	of	the	protocol	are	not	followed.	Based	on	this	information,	it	imperative	to	pay	attention	to	proper	BP	measurement	technique	because	one	misstep	could	cause	a	significant	difference.		
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	 One	of	the	common	aspects	of	protocol	that	is	forgotten	is	waiting	3-5	minutes	to	allow	the	patient	to	rest	before	a	BP	is	taken.	The	significant	difference	between	the	first	and	last	BP	measurement	in	IQ-TY	shows	that	the	effect	of	ignoring	rest	time	is	higher	BP	measurement.	Based	on	a	study	done	by	Ray	et	al.	the	typical	patient	spends	84	minutes	in	the	clinic	per	visit.18	This	gives	the	facility	plenty	of	opportunity	to	find	3-5	minutes	to	allow	the	patient	to	sit	down	and	rest	before	BP	is	measured.	The	current	healthcare	push	for	speed	and	efficiency	may	make	this	more	difficult,	but	it	is	definitely	possible	as	the	visit	is	substantially	longer	than	5	minutes.	It	is	not	worth	rushing	through	a	visit	and	obtaining	improper	measurements	on	the	patient	because	these	data	points	are	intended	to	aid	in	the	diagnosis	and	care	of	the	patient.		Potentially	erroneous	measurements	could	result	in	the	inability	to	provide	the	best	patient	care,	which	should	be	the	primary	goal	of	providers.		 Revisiting	hypothesis	1,	the	differences	between	equipment,	it	is	important	to	consider	how	the	indirect	measure	of	BP	is	used	in	the	medical	management	of	the	patient.	The	trend	a	patient’s	BP	measurements	can	be	a	sign	to	detect	various	diseases.	Although	trend	data	was	not	obtained	in	this	pilot	study,	the	strong	association	between	equipment	as	displayed	in	tables	8	and	9	can	point	to	how	the	various	pieces	of	equipment	can	be	used.	For	example,	say	a	patient	who	was	recording	their	BP	at	home	with	an	Omron	home	automated	unit	came	into	their	primary	care	visit	and	told	the	provider	that	their	recent	BP	readings	were	high.	With	this	information	the	provider	assume	that	the	BP	measurement	in	the	office	will	also	be	high,	though	the	provider	cannot	assume	the	BP	measurements	will	produce	exactly	the	same	value.	Along	with	the	strong	association,	the	two	pieces	of	equipment	normally	used	in	the	clinical	setting,	MA	and	IQ,	only	had	a	mean	difference	of	3	mmHg	for	systolic	BP.	Since	hypertension	categories	change	every	10	mmHg,	the	difference	of	3	mmHg	is	only	a	movement	within	a	single	category.	So	based	on	the	strong	association	and	minimal	difference	between	clinical	devices,	the	different	pieces	of	equipment	all	still	have	value	in	the	clinical	setting.	
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Revisiting	hypothesis	2,	when	protocol	is	not	followed,	it	is	important	to	think	about	how	BP	measurements	are	used	to	categorize	patients.	The	categorization	allows	providers	to	determine	the	best	treatment	to	reduce	hypertension	at	any	stage	and	lower	the	risk	for	potential	cardiovascular	disease.	The	AHA	worked	together	with	the	American	College	of	Cardiology	(ACC)	to	provide	revised	guidelines	for	hypertension	classification	and	management	in	the	fall	of	2017.4	Referring	to	Figure	5,	the	present	cohort	is	profiled	using	the	revised	classifications	and	demonstrates	how	the	data,	generated	by	the	equipment	in	the	context	of	condition	(‘protocol’),	categorized	the	participants.	It	is	clearly	visible	IQ-TY	categorized	more	participants	as	having	elevated	BP,	as	well	as	stage	1	and	stage	2	hypertension	than	all	the	other	conditions	where	protocol	was	followed.	Further,	when	comparing	IQ-TY	to	IQ-PR,	there	was	a	difference	of	8.9	mmHg	for	systolic	and	8.4	mmHg	for	diastolic,	which	is	nearly	the	difference	between	most	hypertension	categories.	Due	to	the	result	suggesting	that	the	lack	of	following	protocol	leads	to	movement	from	a	lower	to	a	higher	hypertension	category,	protocol	must	be	followed	whenever	BP	measurements	are	taken.			 The	revised	BP	classification	presents	the	perfect	opportunity	for	practices	to	revisit	the	way	BP	is	acquired.	Hypertension	is	definitely	an	issue,	as	a	third	of	the	US	population	was	deemed	to	be	hypertensive,	under	the	previous	AHA	categories.			It	is	possible	that	around	half	of	the	US	population	will	now	be	considered	hypertensive,	based	on	the	revised	classification	system.7	Hypertension	is	a	major	issue	and	should	be	treated	when	diagnosed,	but	it	is	imperative	that	those	at	risk	are	first	properly	diagnosed	and	then	properly	treated.	Anti-hypertensive	medications	are	the	most	common	method	to	treat	hypertension,	yet	they	have	many	side	effects.	Individuals	who	truly	need	it	should	be	the	only	ones	taking	medication.		Additional	methods	for	treating	elevated	BP,	such	as	lifestyle	changes,	have	far	fewer	potential	side	effects	and	many	more	potential	benefits.	As	the	AHA	guidelines	have	been	revised	and	BP	thresholds	lowered,	the	number	of	patients	being	placed	on	medication	is	likely.			This	study	would	suggest	that	lack	of	adherence	to	protocol	
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significantly	increases	BP	measurement;	therefore	it	is	imperative	that	the	AHA	protocol	is	followed	and	the	patient’s	BP	measurement	is	not	artificially	elevated	due	to	a	protocol	error.	The	BP	measurement	should	truly	reflect	the	diagnostic	condition	of	the	patient.	The	goal	of	providers	is	to	provide	the	best	patient	care,	and	in	order	to	do	this,	it	is	important	obtain	the	best	data	for	making	critical	diagnostic	decisions.			 It	is	possible,	based	on	the	results	of	this	pilot	study,	that	changing	procedure	to	improve	protocol	adherence	would	likely	have	more	effect	on	BP	measurements	than	a	change	in	equipment	(at	least	for	the	three	devices	used	in	this	study).	So	when	an	equipment	change	is	considered	as	a	means	to	change	workflow,	the	workflow	change	affecting	the	condition	in	which	BP	is	being	measured,	not	the	equipment,	is	likely	the	main	contributor	to	the	fluctuating	BP	measurements.			
Limitations	There	were	several	limitation	with	this	study.	One	of	the	major	ones	was	the	design	of	this	study	as	pre-experimental	and	therefore	there	are	threats	to	internal	and	external	validity.		The	sample	of	participants	was	a	purposive	group	of	volunteers	so	these	results	are	unique	to	the	group	and	cannot	be	translated	to	a	larger	population.			The	fact	that	there	was	only	one	person	taking	BPs	for	the	MA-PR	measurements	is	perhaps	not	clinically	translatable.	One	of	the	major	downfalls	with	manual	measurements	is	that	different	people	take	them	and	they	may	hear	things	differently	or	be	more	or	less	skilled	at	taking	BP,	which	may	lead	to	a	larger	variation	in	measurements.	The	individual	taking	the	MA-PR	measures	in	the	current	study	was	not	a	physician,	nor	were	the	measurements	made	in	a	healthcare	setting,	so	the	white	coat	response	was	not	present.	These	pitfalls	of	manual	readings	could	not	be	address	in	this	study,	but	pose	an	interesting	question	for	a	future	study	to	investigate.		Another	limitation	was	that	there	was	only	a	limited	amount	of	time	with	the	participant,	so	the	number	and	combination	of	conditions	of	measurements	had	to	be	curtailed.	This	prevented	the	
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opportunity	to	fully	cross	device	and	condition,	which	would	have	afforded	the	opportunity	to	test	for	interactions	between	device	and	condition,	rather	than	examining	only	main	effects	of	condition	and	device.		Therefore	this	is	something	that	could	be	addressed	in	a	future	study.			 Finally,	most	of	the	participants	were	younger,	which	may	have	skewed	the	data,	since	many	were	healthy	young	adults	who	generally	have	limited	health	issues	or	elevated	BP.	A	future	study	could	expand	the	sample	and	try	to	get	a	much	more	diverse	participant	group.			 This	study	was	begun	at	the	time	that	the	AHA	released	an	amendment	to	their	diagnostic	thresholds	for	hypertension.		Therefore	these	pilot	results	were	timely	for	assessing	effects	of	equipment,	protocol,	and	resting	on	BP.	The	goal	of	this	pilot	work	was	to	provide	information	about	obtaining	BP	which	could	assist	providers,	improve	diagnostic	practice,	and	the	care	for	patients.			It	also	begins	a	very	important	discussion	on	the	potential	for	the	collecting	reliable	BP	data	that	can	assist	in	correctly	classifying	patients	based	on	the	new	AHA	hypertensive	guidelines.																			
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